Skip to main content

Table 2 Diagnostic accuracy of combinations of serum sCD40L, CA19-9, and/or CEA to detect PDAC by logistic regression in the validation dataset

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

Marker panel* Cut-off point† Sensitivity‡ Specificity
sCD40L 0.45 80.0% 85.5%
CA19-9 0.35 80.0% 72.7%
CEA 0.45 68.9% 60.0%
sCD40L + CA19-9 0.35 80.0% 89.1%
sCD40L + CEA 0.60 80.0% 85.5%
CA19-9 + CEA 0.41 80.0% 70.9%
sCD40L + CA19-9 + CEA 0.45 84.4% 90.9%
  1. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; PDAC, pancreatic ductal adenocarcinoma.
  2. *Each marker is included as a linear term and evaluated as a panel from one to three markers combination.
  3. †Cut-off point refers to the probability cut-off point to classify subjects as having PDAC or non-PDAC in binary logistic regression.
  4. ‡For comparison among panels, the cut-off point ensures a target sensitivity of around 80%.
Back to article page